Clinical Trial

Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)

Name: Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC) — clinical trial record (NCT07545083)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the effectiveness and safety of the combination therapy of Becotatug Vedotin with Pucotenlimab as a possible neoadjuvant therapyand for locally advanced oral/pharyngeal squamous cell carcinoma.

Trial Details

NCT Number	NCT07545083
Lead Sponsor	Shanghai Zhongshan Hospital
Conditions	Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Enrollment	26 participants
Start Date	2026-04
Primary Completion	2027-03 (estimated)
Study Completion	2029-08 (estimated)
Updated on ClinicalTrials.gov	2026-04-22